entospletinib + omeprazole

Entospletinib + omeprazole is a non-standard, theoretical combination of two small-molecule drugs. Entospletinib is a selective spleen tyrosine kinase (Syk) inhibitor developed for hematologic malignancies, particularly B-cell malignancies such as chronic lymphocytic leukemia, small lymphocytic lymphoma, and non-Hodgkin lymphoma. Omeprazole is a widely-used proton pump inhibitor (PPI) that suppresses gastric acid secretion and is indicated for gastroesophageal reflux disease, peptic ulcer disease, and similar conditions. Entospletinib works by inhibiting Syk-mediated signaling required for B-cell receptor activation, thus impairing survival and proliferation of malignant B-cells. Omeprazole irreversibly binds and inhibits the gastric H+/K+ ATPase, reducing acid secretion. There are strong cautions or contraindications against combining entospletinib and omeprazole: proton pump inhibitors, such as omeprazole, are prohibited with entospletinib use in clinical studies due to the risk of drug–drug interactions altering absorption or systemic exposure, potentially compromising efficacy and safety[1].